Related Experiment Video

Updated: Apr 28, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

749

Common therapeutic targets in cardiometabolic disease

Gabrielle Fredman1, Lale Ozcan1, Ira Tabas2

  • 1Department of Medicine, Department of Pathology and Cell Biology, and Department of Physiology, Columbia University, New York, NY 10032-3725, USA.

Science Translational Medicine
|June 6, 2014
PubMed

Insights

Cardiovascular disease and insulin resistance share common pathways. Targeting these shared mechanisms offers a promising strategy for developing drugs that protect against both metabolic disease and cardiovascular disease.

Area of Science:

  • Cardiology
  • Metabolic Research
  • Pathogenesis

Background:

  • Cardiovascular disease (CVD) and insulin resistance syndromes are increasingly recognized as interconnected health issues.
  • Existing treatments often focus on individual conditions, necessitating a broader approach.

Purpose of the Study:

  • To explore the potential for joint therapeutic targets in cardiometabolic research.
  • To identify common upstream pathogenic pathways linking type 2 diabetes and CVD.

Main Methods:

  • Review of mechanistic understanding of cellular pathways in type 2 diabetes and CVD.
  • Analysis of shared pathogenic mechanisms across different cell types.

Main Results:

  • Interactions between CVD and insulin resistance syndromes highlight shared biological pathways.
  • Common upstream pathogenic pathways amenable to therapeutic targeting have been identified.

Conclusions:

  • Developing drugs with protective actions against both metabolic disease and CVD is a key goal.
  • A deep mechanistic understanding can lead to novel therapeutic strategies for cardiometabolic diseases.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
750